Life Sciences
The strategy is focused on creating and building life science companies addressing commercially attractive markets in diseases of high unmet medical needs.
The team has an average experience of 27 years in the sector, with extensive investment track records alongside deep operational experience in drug discovery and development.
Regions
- Western Europe
- United States
Portfolio companies
The Life Sciences strategy aims to build a portfolio of c.15 to 20 preclinical and clinical stage growth opportunities with equity investments of $20-100m per company.
Related people
Life Sciences events calendar
(Year)
Date
Event
Website
2023
14 May 2023
Head of Life Sciences Dr Allan Marchington attends BioEquity Europe in Dublin, Ireland 14 May 2023
2023
16 Jan 2023
Life Sciences Managing Director Toby Sykes attends TABOR Family Office Conference16 Jan 2023
2023
09 Jan 2023
Life Sciences Managing Director Toby Sykes and Consultant Peter Kiener attend 41st Annual J.P. Morgan Annual Health Care Conference09 Jan 2023
2022
09 Nov 2022
Life Sciences Managing Director Simon Tate delivers talk on the history of drug discovery and treatments in pain research at British Neuroscience Association conference09 Nov 2022
2022
21 Sep 2022
Head of Life Sciences Dr Allan Marchington speaks during the State of the Industry Panel at the 22nd Annual Biotech in Europe Forum (BEF)21 Sep 2022
2022
26 May 2022
Life Sciences Associate Director Tracy Weightman speaks at Cancer Research UK Innovation Summit 202226 May 2022
Meet the Life Sciences team
Explore our portfolio companies
Amolyt Pharma
Amolyt Pharma is a clinical stage biotechnology company working to deliver life-changing treatments to patients suffering from rare endocrine and related diseases.
CuraSen Therapeutics
CuraSen Therapeutics is a clinical-stage company developing small molecule therapies to treat neurodegenerative disease.
Wugen Inc
Wugen, Inc., is a clinical-stage biotechnology company developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer.
Get in touch
To find out more about our flexible and sustainable solutions for both providers and users of capital, please contact us.
Contact us
